Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)
| Market Cap | 836.35M+28.4% |
| Revenue (ttm) | 28.73M-83.9% |
| Net Income | -161.12M-766.7% |
| EPS | -2.18-826.7% |
| Shares Out | 84.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 43,538 |
| Open | 10.04 |
| Previous Close | 10.17 |
| Day's Range | 9.87 - 10.04 |
| 52-Week Range | 7.64 - 25.77 |
| Beta | 1.37 |
| Analysts | Buy |
| Price Target | 26.00(+162.63%) |
| Earnings Date | Nov 5, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About GLUE
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$GLUE stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in GLUE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by GLUE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
GLUE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
GLUE Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Other development and discovery programs | $9.80M | 37.10% |
| Collaboration Revenue | $8.97M | 33.96% |
| Interest and other income, net | $5.94M | 22.50% |
| Professional services | $1.70M | 6.45% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New GLUE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to GLUE from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in GLUE
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $35.71M |
| XBIState Street SPDR S&P Biotech ETF | $21.77M |
| IWMiShares Russell 2000 ETF | $19.08M |
| VXFVanguard Extended Market ETF | $11.05M |
| IWOiShares Russell 2000 Growth ETF | $7.06M |
| VTWOVanguard Russell 2000 ETF | $5.93M |
Estimated from each fund’s disclosed top holdings × AUM
GLUE Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from GLUE’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score